Therapeutic efficacy of topical epigallocatechin gallate in murine dry eye

Cornea

Volumn 30, Issue 12, 2011, Pages 1465-1472

  Lee, Hyun Soo ^a,b   Chauhan, Sunil K ^a,b   Okanobo, Andre ^a,b   Nallasamy, Nambi ^a,b   Dana, Reza ^a,b  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

cornea; dry eye disease; epigallocatechin gallate; lymphangiogenesis

Indexed keywords

CD11B ANTIGEN; CHEMOKINE; EPIGALLOCATECHIN GALLATE; HYALURONIC ACID; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN D;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORNEA; CORNEA EPITHELIUM; CYTOTOXICITY; DRUG EFFICACY; DRY EYE; FEMALE; FLUORESCENCE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LYMPH VESSEL; LYMPHANGIOGENESIS; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION;

ANIMALS; ANTIOXIDANTS; CATECHIN; CHEMOKINES; CORNEA; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; FEMALE; FLUORESCEIN; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; MICE; MICE, INBRED C57BL; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR D;

EID: 81355160345     PISSN: 02773740     EISSN: 15364798     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31821c9b5a     Document Type: Article

References (33)

1. Schaumberg DA, Sullivan DA, Buring JA, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
2. Pflugfelder SC, de Paiva CS, Li DQ, et al. Epithelial-immune cell interaction in dry eye. Cornea. 2008;27(suppl 1):S9-S11.
3. Yoon KC, De Paiva CS, Qi H, et al. Expression of Th-1 chemokines and chemokine receptors on the ocular surface of C57BL/6 mice: effects of desiccating stress. Invest Ophthalmol Vis Sci. 2007;48:2561-2569.
4. Chauhan SK, El Annan J, Ecoiffier T, et al. Autoimmunity in dry eye is due to resistance of Th17 to Treg suppression. J Immunol. 2009;182: 1247-1252.
5. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114: 76-79.
6. Ecoiffier T, El Annan J, Rashid S, et al. Modulation of integrin alpha4beta1 (VLA-4) in dry eye disease. Arch Ophthalmol. 2008;126:1695-1699.
7. Goyal S, Chauhan SK, Zhang Q, et al. Amelioration of murine dry eye disease by topical antagonist to chemokine receptor 2. Arch Ophthalmol. 2009;127:882-887.
8. Luo L, Li DQ, Doshi A, et al. Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest Ophthalmol Vis Sci. 2004;45: 4293-4301.
9. Stern ME, Gao J, Schwalb TA, et al. Conjunctival T cell subpopulations in Sjögren's and non-Sjögren's patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609-2614.
10. Gillespie K, Kodani I, Dickinson DP, et al. Effects of oral consumption of the green tea polyphenol EGCG in a murine model for human Sjogren's syndrome, an autoimmune disease. Life Sci. 2008;83:581-588.
11. Aktas O, Prozorovski T, Smorodchenko A, et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J Immunol. 2004;173: 5794-5800.
12. Yoneyama S, Kawai K, Tsuno NH, et al. Epigallocatechin gallate affects human dendritic cell differentiation and maturation. J Allergy Clin Immunol. 2008;121:209-214.
13. Blackwell TS, Christman JW. The role of nuclear factor-kappaB in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997;17:3-9.
14. Sueoka N, Suganuma M, Sueoka E, et al. A new function of green tea: prevention of lifestyle-related diseases. Ann N Y Acad Sci. 2001;928: 274-280.
15. Wheeler DS, Catravas JD, Odoms K, et al. Epigallocatechin-3-gallate, a green tea-derived polyphenol, inhibits IL-1 beta-dependent proinflammatory signal transduction in cultured respiratory epithelial cells. J Nutr. 2004;134:1039-1044.
16. Shin HY, Kim SH, Jeong HJ, et al. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NF-kappaB in HMC-1 cells. Int Arch Allergy Immunol. 2007;142: 335-344.
17. Barabino S, Shen L, Chen L, et al. The controlled-environment chamber: a new mouse model of dry eye. Invest Ophthalmol Vis Sci. 2005;46: 2766-2771.
18. Lemp MA. Report of the National Eye Institute/Industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221-232.
19. Rashid S, Jin Y, Ecoiffier T, et al. Topical omega-3 and omega-6 fatty acids for treatment of dry eye. Arch Ophthalmol. 2008;126:219-225.
20. Chung ES, Saban DR, Chauhan SK, et al. Regulation of blood vessel versus lymphatic vessel growth in the cornea. Invest Ophthalmol Vis Sci. 2009;50:1613-1618.
21. Yeh S, Song XJ, Farley W, et al. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci. 2003;44: 124-129.
22. Xing D, Bonanno JA. Hypoxia preconditioning protection of corneal stromal cells requires HIF1alpha but not VEGF. Mol Vis. 2009;15: 1020-1027.
23. Kapoor M, Howard R, Hall I, et al. Effects of epicatechin gallate on wound healing and scar formation in a full thickness incisional wound healing model in rats. Am J Pathol. 2004;165:299-307.
24. Donà M, Dell'Aica I, Calabrese F, et al. Neutrophil restraint by green tea: inhibition of inflammation, associated angiogenesis, and pulmonary fibrosis. J Immunol. 2003;170:4335-4341.
25. Shankar S, Ganapathy S, Hingorani SR, et al. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci. 2008;13:440-452.
26. Shen L, Barabino S, Taylor AW, et al. Effect of the ocular microenvironment in regulating corneal dendritic cell maturation. Arch Ophthalmol. 2007;125:908-915.
27. Kimura K, Teranishi S, Nishida T. Interleukin-1beta-induced disruption of barrier function in cultured human corneal epithelial cells. Invest Ophthalmol Vis Sci. 2009;50:597-603.
28. Boisvert WA, Rose DM, Johnson KA, et al. Up-regulated expression of the CXCR2 ligand KC/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression. Am J Pathol. 2006;168:1385-1395.
29. Melgarejo E, Medina MA, Sánchez-Jiménez F, et al. (-)-Epigallocatechin-3-gallate interferes with mast cell adhesiveness, migration and its potential to recruit monocytes. Cell Mol Life Sci. 2007;64:2690-2701.
30. Goyal S, Chauhan SK, Dana R, et al. Evidence of corneal lymphangiogenesis in dry eye disease: a potential link to adaptive immunity? Arch Ophthalmol. 2010;128:819-824.
31. Jung YD, Kim MS, Shin BA, et al. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br J Cancer. 2001;84:844-850.
32. Kojima-Yuasa A, Hua JJ, Kennedy DO, et al. Green tea extract inhibits angiogenesis of human umbilical vein endothelial cells through reduction of expression of VEGF receptors. Life Sci. 2003;73:1299-1313.
33. McLarty J, Bigelow RL, Smith M, et al. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009;2: 673-682.